MISSION, VISION AND VALUES

Since its establishment in 1928, the Institute has been a key player in major clinical and healthcare achievements, and it continues to be a benchmark in cancer research.

The Institute operates as a public service characterized by a high level of diagnostic, therapeutic, and research activities, always guided by fundamental principles that are essential: respect for human dignity, the protection of the patient, and their right to receive the most appropriate care and treatments.

FROM THE LABORATORY TO THE PATIENT’S BEDSIDE AND BACK

The Institute conducts translational research that follows the path “from bench to bedside” and back, uniting clinical data with laboratory evidence. From the systematic evaluation of trial results to real-world evidence, feedback signals are continuously brought back from the clinic to the laboratory.

The Institute has programs and projects across all research phases: preclinical, clinical, and epidemiological-healthcare. These studies are carried out through multidisciplinary teams, constantly working to progress and share results.

ACCESS TO INNOVATIVE DRUGS THROUGH CLINICAL STUDIES

INT is the national coordinator of numerous national and international clinical trials, sponsored by industry and promoted by public bodies, including early-phase studies. By participating in these studies, patients can contribute to scientific progress and access drugs otherwise unavailable, including highly specific and personalized drugs—an opportunity for treatment and care. For this reason, study participation is always considered an additional patient benefit.

A PERSONALIZED APPROACH

Thanks to precision medicine, the Institute promotes the personalization of pharmacological therapy, a hallmark of modern medicine. We strive to offer patients personalized screening, differential diagnostics, pharmacological therapy (and radiotherapy, including surgical radiotherapy), and monitoring programs tailored to their profiles and specific conditions. Personalized interventions target the tumor and its microenvironment, interact with the immune system, and consider the individual as a whole in a holistic vision of patient care.

The Institute is also very active in secondary prevention, in identifying prognostic-predictive profiles, and in optimizing the use of new immunological drugs.

EDUCATION AND TEACHING IN ONCOLOGY

The Institute is dedicated to training and education for healthcare staff, with teaching activities conducted through agreements with universities. To date, the Institute hosts 139 university medical residency programs.